Zim Laboratories Limited
Incorporated in 1989, Zim LaboratoriesLtd manufactures formulation drugs andpre formulation ingredients in India andmarkets and sells these within and outside India
What Zim files
- Others74
- Investor Meet33
- Important19
- Board Meeting13
- Updates9
- JV/Acquisition6
Zim Laboratories Limited has made the audio recording of its Q1 FY27 Earnings Conference Call available on the company's website for investor access.
Zim Laboratories Limited has informed the Exchange about Copy of Newspaper Publication
Zim Laboratories' Q1 FY27 Total Operating Income grew 31.2% YoY to ₹94.2 Cr. EBITDA dropped 40% to ₹3.4 Cr (3.7% margin) due to higher costs, resulting in a ₹4.0 Cr net loss. Innovative product revenue tripled YoY to ₹13.8 Cr. CAPA remediation is largely complete, with 17 filings and 10...
ZIM Laboratories' Board approved consolidated Q1FY27 results. Revenue from operations stood at ₹94.18 Cr, with the company reporting a net loss of ₹4.02 Cr for the quarter ended June 30, 2026.
ZIM Laboratories Limited has scheduled a Q1FY27 Earnings Conference Call on Friday, August 7, 2026, at 12:00 PM IST. Key company representatives, including Director (Finance) Mr. Zulfiquar Kamal and CFO Mr. Shyam Mohan Patro, will participate.